Skip to main content
Independent federal grant matching. Not affiliated with any government agency. Get free access and see which open grants fit your organization.
Open for applications

Glioblastoma Therapeutics Network (GTN) (U19 Clinical Trial Required)

National Institutes of Health · Opportunity number RFA-CA-27-005

View the official notice on Grants.gov
87 days left (deadline Jan 11, 2027)

Details summarized from the official notice as of Oct 15, 2026. Always confirm eligibility, deadlines and requirements in the official notice before applying.

Independent platform. Not affiliated with or endorsed by any government agency. Data from public federal sources.

Key facts

Opportunity numberRFA-CA-27-005
AgencyNational Institutes of Health
Department of Health and Human Services
Assistance listing (ALN, formerly CFDA)93.394, 93.395
PostedAug 31, 2026
DeadlineJan 11, 2027
Award ceiling$700,000
Expected number of awards4
Estimated total program funding$4,400,000
Cost sharing or matching requiredNo
Funding typeCooperative agreement
CategoryHealth
Last updated hereOct 15, 2026

Summary from the notice

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits applications for research on novel therapies for adult glioblastoma (GBM). The goal is to improve the treatment of adult GBM by developing novel effective agents that can cross the blood brain barrier (BBB) and testing them clinically. Successful early-stage trials of new drugs from this NOFO would transition seamlessly to later stage trials using well-established NCI clinical trial mechanisms.To implement this concept, a highly collaborative GBM Therapeutics Network (GTN) of cross-cutting teams will be established, each team capable of driving therapeutic agent(s) from pre-clinical development, through investigational new drugs (IND) studies, into pilot clinical studies in humans. Appropriate therapeutic agents include: (1) novel agents or (2) agents or combinations approved for other indications and repurposed for treatment of GBM following appropriate preclinical studies. The scope of the NOFO, from late pre-clinical through early (Phase 0/1) clinical studies, uniquely spans a gap in the GBM drug development process.

Who can apply

The official notice lists these applicant types as eligible:

  • Other Native American tribal organizations
  • Public and Indian housing authorities
  • Private colleges and universities
  • For-profit organizations other than small businesses
  • Others named in the notice (see the eligibility text)
  • Public and state colleges and universities
  • State governments
  • Nonprofits with 501(c)(3) status (other than colleges)
  • City or township governments
  • Special district governments
  • Small businesses
  • Federally recognized tribal governments
  • Independent school districts
  • Nonprofits without 501(c)(3) status (other than colleges)
  • County governments

Who should take a closer look

  • Small businesses
  • Nonprofits
  • Colleges and universities
  • State governments
  • Local governments
  • Tribal governments and organizations
  • Larger for-profit companies

Not listed as eligible

  • Individuals

Unless the eligibility text in the notice names you, this opportunity is probably not for you.

Eligibility details from the notice

Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organization) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.

Registrations you will likely need

Most applications submitted through Grants.gov need the following. Registration can take several weeks, so start early. The notice lists the exact requirements.

Similar open opportunities

Limited Competition: Small Grant Program for the NCATS Clinical and Translational Science Award (CTSA) Program (R03 Clinical Trial Optional)

National Institutes of Health · PAR-25-155

Deadline: Oct 19, 2026 (3 days left) Up to: $50,000 Health

Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)

National Institutes of Health · RFA-CA-27-021

Deadline: Oct 19, 2026 (3 days left) Up to: $600,000 Health

Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)

National Institutes of Health · RFA-CA-27-020

Deadline: Oct 19, 2026 (3 days left) Up to: $600,000 Health